ENLIVEN THERAPEUTICS INC. - COMMON STOCK

21,69

10-января-25 13:15:48

15 мин. задержка

Акции

-2,46

-10,19%

Сегодняшний диапазон

21,56 - 24,21

ISIN

N/A

Источник

NASDAQ

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

28 сен 2024 09:35:00 Источник Nasdaq GlobeNewswire
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

18 сен 2024 16:05:07 Источник Nasdaq GlobeNewswire
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

13 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire
Enliven Therapeutics to Present at Two Upcoming Investor Conferences

29 май 2024 16:05:00 Источник Nasdaq GlobeNewswire
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

14 май 2024 16:05:00 Источник Nasdaq GlobeNewswire
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

11 апр 2024 07:55:00 Источник Nasdaq GlobeNewswire
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

09 апр 2024 16:05:00 Источник Nasdaq GlobeNewswire
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

28 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.